FDA approves first treatment for rare type of glioma
The US Food and Drug Administration (FDA) has granted accelerated approval for Modeyso (dordaviprone) for the treatment of patients one year of age and older with diffuse midline glioma harbouring an H3 K27M mutation with progressive disease following prior therapy.
The FDA has stated that continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase III ACTION confirmatory trial.
Modeyso is the first treatment option approved by the FDA for this ultra-rare and aggressive brain tumour that affects an estimated 2,000 people in the US each year.
The disease is characterised by rapid progression and historically has had no effective systemic treatment options.
“This is a major turning point in neuro-oncology,” said Patrick Wen, Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute and Professor of Neurology, Harvard Medical School. “For the first time, we have an FDA-approved therapy for patients with recurrent H3 K27M-mutant diffuse midline glioma. While outcomes remain challenging for many patients, the objective responses observed with dordaviprone, including durable benefit in some patients, represent a meaningful advancement. This therapy was developed with the underlying biology of the tumour in mind and introduces a new treatment option for a population with historically limited choices.”
Durable benefit in some glioma patients
The FDA’s decision was based on an integrated efficacy analysis of 50 patients with recurrent H3 K27M-mutant diffuse midline glioma, selected from five open-label clinical studies based on prespecified eligibility criteria.
The overall response rate (ORR), as assessed by blinded independent central review (BICR) using Response Assessment in Neuro-Oncology (RANO) 2.0 criteria, was 22%, with an additional responder identified by integrated RANO 2.0. Among responders, the median duration of response was 10.3 months, with 73% maintaining their response for at least six months and 27% for at least 12 months.
Modeyso is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and also inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.
Diana Turner, Senior Digital Content Editor, DDW
